What Is Going On With My Hair? A Clinical Guide to Female Hair Loss and Changes

Why Women Lose Hair: The Four Core Mechanisms

Hair loss in women rarely has a single cause. Most cases trace back to one of four biological pathways: hormonal imbalance, nutritional deficiency, physical or psychological stress, or autoimmune or inflammatory disease. Getting the right diagnosis is not optional; treating androgenetic alopecia with iron supplements when ferritin is normal will accomplish nothing.

The Hair Cycle and Why It Goes Wrong

Each hair follicle moves through three phases. The anagen (growth) phase lasts 2 to 6 years. The catagen (transition) phase lasts about 2 weeks. The telogen (resting and shedding) phase lasts roughly 3 months before the follicle re-enters anagen.

On a healthy scalp, about 85 to 90 percent of follicles sit in anagen at any given time. When the body perceives a stressor, whether that stressor is low ferritin, a fever, surgery, or plummeting estrogen, large numbers of follicles leave anagen early and enter telogen simultaneously. The shed appears 2 to 4 months later. This delay is one reason women often cannot connect the hair loss to its actual cause.

Androgenetic Alopecia (Female-Pattern Hair Loss)

Androgenetic alopecia (AGA) is the most common form of hair loss in women. The American Academy of Dermatology estimates it affects up to 40 percent of women by menopause. Unlike the male pattern (receding hairline), female AGA typically presents as diffuse thinning across the crown and widening of the central part, with the frontal hairline preserved.

Dihydrotestosterone (DHT), a potent androgen converted from testosterone by the enzyme 5-alpha-reductase, binds to receptors in genetically susceptible follicles and shortens the anagen phase progressively. Estrogen normally counterbalances this effect on the scalp. When estrogen drops during perimenopause, the relative androgenic environment intensifies, accelerating follicle miniaturization even without any absolute rise in testosterone. A 2021 review in the Journal of the American Academy of Dermatology confirmed this estrogen-withdrawal mechanism in postmenopausal women.

Telogen Effluvium

Telogen effluvium (TE) is the abrupt, diffuse shedding that follows a metabolic shock. Common triggers include:

• Childbirth (postpartum TE typically peaks at 3 months after delivery)
• Major surgery or general anesthesia
• Acute illness with high fever, including COVID-19
• Rapid weight loss of more than 15 percent body weight
• Thyroid dysfunction (both hypothyroidism and hyperthyroidism)
• Significant psychological stress sustained over weeks

TE is almost always self-limiting. Hair density typically normalizes within 6 to 9 months once the trigger is removed, provided nutritional status is adequate. A 2020 clinical review in Skin Appendage Disorders described COVID-19-associated TE as presenting 2 to 3 months after acute illness in a high proportion of hospitalized patients.

Autoimmune and Inflammatory Causes

Alopecia areata, lichen planopilaris, and frontal fibrosing alopecia represent inflammatory pathways that require dermatologic evaluation and are beyond standard hormonal management. Alopecia areata affects roughly 2 percent of the population and presents as well-demarcated round patches of hair loss rather than diffuse thinning. Scarring alopecias (lichen planopilaris, frontal fibrosing alopecia) can be permanent if untreated. Any woman presenting with scalp itching, burning, redness, or patchy loss should be referred to a board-certified dermatologist promptly.

The Hormone Connection: Estrogen, Progesterone, and Androgens

Hormones are the most commonly overlooked driver of hair changes in women over 35. The relationship is dose-dependent and bidirectional, meaning too much or too little of several hormones can each produce hair loss through different mechanisms.

Estrogen's Protective Role

Estrogen receptors exist on human hair follicle cells. Estrogen extends the anagen phase and appears to modulate the local conversion of testosterone to DHT. Women taking combined oral contraceptives with a progestogen that has low androgenic activity (such as drospirenone) often report improved hair density. Women who discontinue the pill may experience a transient TE episode as estrogen levels fall.

During perimenopause and menopause, serum estradiol can drop from premenopausal levels of 100 to 400 pg/mL down to below 20 pg/mL. The Menopause Society (formerly NAMS) 2023 position statement on menopause hormone therapy notes that hair thinning is among the quality-of-life symptoms that can be addressed by systemic hormone therapy.

Progesterone's Role

Progesterone is a weak inhibitor of 5-alpha-reductase. Falling progesterone in the perimenopause period may therefore contribute to higher local DHT availability at the follicle. Some women using topical or oral progesterone as part of hormone replacement therapy report stabilization of hair shedding, though randomized controlled trial data specifically on progesterone and AGA in women remains thin.

Thyroid Hormones

Both overt hypothyroidism and hyperthyroidism produce diffuse hair thinning. The American Thyroid Association recommends TSH measurement as part of any workup for unexplained hair loss. A TSH above 4.0 mIU/L in the context of hair shedding warrants treatment discussion. Hair regrowth after thyroid normalization is typical but may take 6 to 12 months.

DHEA, Cortisol, and Insulin

Chronic elevation of cortisol from sustained psychological stress accelerates catagen entry in follicles. High insulin from insulin resistance increases ovarian androgen production, which explains why women with polycystic ovary syndrome (PCOS) show disproportionate rates of AGA at younger ages. A 2022 analysis in Frontiers in Endocrinology reported that women with PCOS had a 3.7-fold higher odds of AGA compared with age-matched controls.

Nutritional Deficiencies That Cause Hair Loss

Diet and nutrient stores matter enormously. Hair follicles are among the most metabolically active structures in the body, and they deprioritize nutrients under scarcity.

Iron and Ferritin

Ferritin, the iron-storage protein, is the single most important nutritional marker to check. Serum ferritin below 30 ng/mL is associated with hair shedding even when complete blood count (CBC) shows no anemia. Many laboratories flag ferritin as "normal" at levels as low as 12 ng/mL. Dermatologists typically target a ferritin of 70 ng/mL or above for hair-related outcomes.

Supplementing with ferrous sulfate 325 mg daily (containing 65 mg elemental iron) taken with vitamin C on an empty stomach is the standard approach when ferritin is low. Repeat ferritin testing at 3 months is appropriate to confirm absorption.

Zinc

Zinc deficiency produces a diffuse telogen effluvium. Serum zinc below 70 mcg/dL warrants repletion. Standard supplementation is 25 to 50 mg of elemental zinc daily. Note that zinc competes with copper for absorption, so long-term high-dose zinc requires copper 2 mg daily alongside it.

Vitamin D

Vitamin D receptors are expressed in hair follicle keratinocytes. A 2019 meta-analysis in Skin Pharmacology and Physiology (6 studies, N=296) found significantly lower serum 25(OH)D levels in patients with telogen effluvium compared with controls. Optimal 25(OH)D for hair is generally considered above 40 ng/mL. Supplementing with vitamin D3 2,000 to 5,000 IU daily to reach this target is reasonable.

Protein and Biotin

Hair is approximately 95 percent keratin, a protein. Women eating fewer than 50 grams of protein daily risk hair loss from substrate deficiency alone. Biotin deficiency is rare outside of people consuming raw egg whites regularly or taking certain anticonvulsants. Biotin supplements are heavily marketed for hair but have meaningful evidence only in confirmed deficiency. The FDA has also noted that high-dose biotin (above 5,000 mcg daily) can interfere with common immunoassay lab tests, including thyroid and troponin panels.

Diagnosing Your Hair Loss: Which Tests to Order

A rational diagnostic sequence avoids over-testing while catching the most common correctable causes. The following stepwise approach is what HealthRX clinicians apply when evaluating women with hair complaints.

First tier (order in all women with hair loss):

| Test | Target Range for Hair Health | |---|---| | Serum ferritin | 70 ng/mL or above | | TSH | 0.5 to 2.5 mIU/L (optimal) | | CBC with differential | Rule out anemia | | 25(OH) vitamin D | 40 to 60 ng/mL | | CMP (basic metabolic panel) | Rule out systemic disease |

Second tier (add when first tier is unremarkable or hormonal cause is suspected):

| Test | Relevance | |---|---| | Free and total testosterone | Elevated in PCOS and adrenal hyperplasia | | DHEA-S | Adrenal androgen excess | | Prolactin | Hyperprolactinemia causes TE | | Estradiol (E2) | Baseline hormonal status, especially perimenopause | | SHBG | Low SHBG raises free androgen availability | | Fasting insulin and glucose | Insulin resistance screening | | Zinc and copper | Nutritional screen if diet is restricted |

A board-certified dermatologist may also perform a trichoscopy (dermoscopy of the scalp) or a 4 mm punch biopsy if the clinical picture suggests scarring alopecia or alopecia areata.

Evidence-Based Treatment Options

Treatment effectiveness depends entirely on matching the intervention to the mechanism. This section covers options supported by controlled trial data or guideline endorsement.

Minoxidil

Topical minoxidil remains the only FDA-approved topical treatment for female-pattern hair loss. The 2% formulation was approved specifically for women. The 5% formulation is used off-label in women and produces modestly better results.

In a 48-week randomized controlled trial comparing minoxidil 5% foam to placebo in women with AGA, the 5% group showed a statistically significant improvement in non-vellus hair count per cm² (P<0.001) and patient-reported global assessment scores. Full trial data are available via the FDA prescribing information archive.

Oral minoxidil at low doses (0.25 to 1.25 mg daily) is gaining traction as an off-label alternative for women who find topical application inconvenient. A 2020 retrospective study in the Journal of the American Academy of Dermatology (N=100 women) reported 79 percent of patients showing improvement in hair density at 6 months on oral minoxidil doses of 0.25 to 2.5 mg. Side effects at low doses are generally limited to mild hypertrichosis (fine body hair growth).

Hormone Replacement Therapy

Systemic estrogen therapy does not directly treat AGA but may slow progression by restoring the protective estrogenic scalp environment. Women who start hormone therapy at menopause for other indications (vasomotor symptoms, bone protection) often report stabilization of hair shedding as a secondary benefit.

The choice of progestogen matters. Oral micronized progesterone (e.g., Prometrium 200 mg cyclic or 100 mg daily continuous) has the most favorable androgenic profile of available progestogens. Synthetic progestins with higher androgenic activity (levonorgestrel, norethindrone acetate) may worsen hair loss in androgen-sensitive women. The 2023 Menopause Society hormone therapy position statement specifically addresses progestogen selection in the context of androgenic side effects.

Anti-Androgens

Spironolactone at 50 to 200 mg daily blocks the androgen receptor and is the most commonly prescribed systemic treatment for female AGA and PCOS-related hair loss in the United States. A 2020 review in the International Journal of Dermatology summarized data from 8 observational studies and found that 74 percent of women showed stabilization or improvement of AGA on spironolactone. The primary pooled analysis is indexed at PubMed.

Spironolactone is teratogenic and must not be used during pregnancy. Women of reproductive potential require reliable contraception while taking it. Common side effects include increased urination (the drug is also a mild diuretic), menstrual irregularity, and breast tenderness.

Finasteride (1 mg daily), a 5-alpha-reductase inhibitor approved for male-pattern baldness, is used off-label in postmenopausal women with AGA. A 2012 trial in the Journal of the American Academy of Dermatology (N=37 postmenopausal women) showed no significant benefit over placebo at this dose, though higher doses (2.5 to 5 mg) used in subsequent studies showed more promise in postmenopausal populations.

Platelet-Rich Plasma (PRP)

PRP injections deliver concentrated growth factors (including PDGF, VEGF, and EGF) directly to the scalp. A 2019 meta-analysis in Aesthetic Plastic Surgery (14 RCTs, N=460) found that PRP significantly increased hair density and thickness in AGA patients compared with controls. Results require 3 monthly sessions initially, then maintenance every 3 to 6 months. PRP is not covered by insurance and costs range from $500 to $1,500 per session depending on geography.

Low-Level Laser Therapy (LLLT)

LLLT devices (caps, combs, or in-office panels) deliver red light at 630 to 670 nm wavelengths to stimulate follicular metabolism. The FDA has cleared several LLLT devices for hair growth under the 510(k) pathway. A 2014 randomized, double-blind trial in the American Journal of Clinical Dermatology (N=128) found that a home-use LLLT device produced a 39 percent increase in hair count over 26 weeks versus a 3 percent increase in the sham group (P<0.001).

Nutrafol and Cosmeceutical Supplements

Nutrafol is a branded supplement containing ashwagandha, marine collagen peptides, biotin, curcumin, and saw palmetto. A 2018 randomized, double-blind, placebo-controlled trial (N=40 women with self-perceived hair thinning) published in the Journal of Drugs in Dermatology showed significantly greater hair growth rate and thickness in the Nutrafol group at 6 months. The trial is indexed at PubMed. Limitations include industry funding and a small sample size. The supplement is generally safe, but saw palmetto may have mild 5-alpha-reductase inhibitory activity, relevant for women considering pregnancy.

What Healthy Hair Actually Looks Like: Setting Realistic Expectations

Normal daily shedding is 50 to 100 hairs. Anything over 100 hairs per day for more than 2 consecutive weeks warrants evaluation. Density peaks in the late 20s and declines gradually after 40 even without pathology.

Treatment timelines are longer than most patients expect:

• Minoxidil: initial shedding increase for the first 4 to 6 weeks (follicles being pushed into a new anagen cycle), then visible improvement by week 16, peak response at 12 months
• Spironolactone: stabilization of shedding at 3 to 6 months, density improvement taking up to 12 months
• Iron repletion: shed reduction at 3 months, density improvement at 6 to 9 months
• Hormone therapy: variable, typically 6 to 12 months to assess hair-specific response

Women who discontinue any of these treatments typically see shedding return to pretreatment levels within 3 to 6 months, particularly with minoxidil and spironolactone.

Special Situations: Hair Loss in Perimenopause and After GLP-1 Use

Perimenopause and Menopause

Perimenopause is the period of highest risk for new-onset or worsening female AGA. The hormonal transition from regular cycles to menopause takes an average of 4 to 8 years. Follicular DHT sensitivity increases as estrogen levels become erratic and then fall. Women in this period benefit from early evaluation and early intervention. Waiting to treat AGA until after noticeable thinning allows more miniaturization to occur.

"Early recognition and treatment of female-pattern hair loss during the perimenopausal transition offers the best chance of preserving density before irreversible follicle miniaturization progresses," according to guidance published by the American Academy of Dermatology. Monitoring hair part width and using a standardized photo protocol (same lighting, angle, and hair part) every 3 months allows objective tracking.

Hair Loss After GLP-1 Receptor Agonist Use

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have produced reports of hair shedding. This is a telogen effluvium from rapid caloric restriction and weight loss rather than a direct drug effect. In STEP-1 (N=1,961), 3 percent of semaglutide 2.4 mg users reported alopecia versus 1 percent of placebo users. The primary STEP-1 results are published in the New England Journal of Medicine.

The shedding typically appears 3 to 4 months after initiating rapid weight loss and self-resolves as weight stabilizes. Maintaining protein intake at a minimum of 1.2 grams per kilogram of body weight daily and keeping ferritin above 70 ng/mL are the most actionable preventive steps.

When to Seek Immediate Evaluation

Some hair loss patterns require prompt referral rather than watchful waiting:

• Patches of complete hair loss with scalp scaling or redness (possible lichen planopilaris or seborrheic dermatitis with secondary alopecia)
• Frontal hairline recession with eyebrow thinning in a woman over 50 (frontal fibrosing alopecia, a scarring process)
• Sudden diffuse loss of more than 50 percent of hair volume over 4 weeks
• Any hair loss accompanied by systemic symptoms (fatigue, joint pain, facial rash) suggesting lupus or another autoimmune condition

A TSH, ANA (antinuclear antibody), and dermatology referral are the appropriate first steps when these patterns appear. Delaying evaluation in scarring alopecias risks permanent follicle destruction.